TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Endometriosis as a risk factor for ovarian cancer
Key Statistics
- 1 in 10 — Premenopausal women with endometriosis (UK)
- 2% → 4% — Lifetime EOC risk without vs with endometriosis
- RR 2.46 — EOC risk with ovarian endometriosis (Saavalainen)
Don't-miss facts
-
Endometriosis roughly doubles lifetime EOC risk (2/100 → 4/100); ESHRE: +1.2% absolute background risk added
-
EAOC = endometrioid (EC) + clear cell carcinoma (CCC) subtypes
-
Only ovarian endometriosis (not peritoneal/deep) significantly raises overall EOC risk – RR 2.46 (Saavalainen)
-
No screening recommended – UKCTOCS and UKFOCS both failed to show mortality benefit
-
ESHRE does not recommend BSO for EAOC risk reduction (NNH 24 for all-cause mortality)
-
Tubal ligation gives best EAOC-specific risk reduction (EC RR 0.54, CCC RR 0.55) – offer once family complete
-
CHC ≥5y use → 20.5% overall EOC risk reduction (21% EC, 27% CCC); protection lasts decades
-
NICE: PARP inhibitor maintenance for advanced EOC responding to chemo, regardless of BRCA status
Risk reduction – effective vs unproven
Effective: tubal ligation, deep excisional surgery, CHC, DMPA, LNG-IUS
No benefit shown: aspirin, dienogest (no long-term data), BSO not ESHRE-recommended
Abbreviation Key
- EOC — epithelial ovarian cancer
- EZH2 — enhancer of zeste homolog 2 (methyltransferase)
- EAOC — endometriosis-associated ovarian cancer
- UKCTOCS — UK Collaborative Trial of Ovarian Cancer Screening
- CCC — clear cell carcinoma
- UKFOCS — UK Familial Ovarian Cancer Screening Trial
- EC — endometrioid carcinoma
- ESHRE — European Society of Human Reproduction and Embryology
- ARID1A — AT-rich interaction domain 1A (tumour suppressor gene)
- NICE — National Institute for Health and Care Excellence
- SWI-SNF — SWItch/Sucrose Non-Fermentable chromatin
- remodelling complex OS — overall survival
- DMPA — depot medroxyprogesterone acetate
- PFS — progression-free survival
- LNG-IUS — levonorgestrel-releasing intrauterine system
- DFS — disease-free survival
Source: Campbell R et al. Endometriosis as a risk factor for ovarian cancer: an update on screening, risk reduction, treatment and prognosis. The Obstetrician & Gynaecologist 2024;26:189–196. doi:10.1111/tog.12948
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).